1. Home
  2. NRIX vs VRE Comparison

NRIX vs VRE Comparison

Compare NRIX & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.17

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Veris Residential Inc.

VRE

Veris Residential Inc.

HOLD

Current Price

$14.74

Market Cap

1.4B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
VRE
Founded
2009
1949
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2020
1994

Fundamental Metrics

Financial Performance
Metric
NRIX
VRE
Price
$19.17
$14.74
Analyst Decision
Strong Buy
Buy
Analyst Count
13
3
Target Price
$29.08
$18.67
AVG Volume (30 Days)
1.2M
506.1K
Earning Date
02-12-2026
02-23-2026
Dividend Yield
N/A
2.15%
EPS Growth
N/A
N/A
EPS
N/A
0.68
Revenue
$83,687,000.00
$291,348,000.00
Revenue This Year
$59.40
$4.85
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$23.69
Revenue Growth
48.32
6.39
52 Week Low
$8.18
$13.69
52 Week High
$22.50
$17.18

Technical Indicators

Market Signals
Indicator
NRIX
VRE
Relative Strength Index (RSI) 55.82 47.84
Support Level $18.12 $14.61
Resistance Level $19.50 $15.23
Average True Range (ATR) 1.05 0.36
MACD -0.08 -0.01
Stochastic Oscillator 67.22 29.79

Price Performance

Historical Comparison
NRIX
VRE

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About VRE Veris Residential Inc.

Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.

Share on Social Networks: